High Neutrophil to Lymphocyte Ratio Prognostic in Early Breast Cancer

High Neutrophil to Lymphocyte Ratio Prognostic in Breast Cancer
High Neutrophil to Lymphocyte Ratio Prognostic in Breast Cancer

(HealthDay News) -- Presurgery high neutrophil to lymphocyte ratio (NLR) is a prognostic variable of worse outcome in Caucasian patients with early breast cancer, according to a study published online March 7 in ESMO Open: Cancer Horizons.

Michele Orditura, M.D., Ph.D., from the Second University of Naples School of Medicine in Italy, and colleagues conducted a retrospective analysis involving 300 Caucasian patients with early breast cancer. Patients were classified as having low or high NLR (134 and 166 patients, respectively), and the correlation with distant metastasis-free survival (DMFS) was measured.

The researchers found that for one, three, six, nine, 12, and 15 years, the DMFS rates were 100, 98.9, 91.7, 82.7, 82.7, and 82.7 percent, respectively, for the low NLR cohort and 99.4, 94.3, 84.5, 69.2, 66.0, and 51.4 percent, respectively, for the high NLR cohort, with a statistically significant association. On multivariate analysis, independent prognostic factors related to poor recurrence rate were premenopausal status (hazard ratio [HR], 2.78), N1 stage (HR, 2.31), and high NLR value (HR, 2.64). In propensity score-matched analysis, premenopausal status, N1 stage, and high NLR values were confirmed as independent prognostic variables of worse outcome (HRs, 2.94, 2.77, and 2.52, respectively).

"This is the first study, to our knowledge, to show a significant correlation between high NLR and worse prognosis in Caucasian patients with early breast cancer by means of propensity score-matched analysis," the authors write.

Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs